Concrete Pumping (NasdaqCM:BBCP) Q4 2025 Earnings call January 13, 2026 05:00 PM ET Company ParticipantsIain Humphries - CFOCody Slach - External Director of Investor RelationsBruce Young - CEOConference Call ParticipantsTim Mulrooney - AnalystAndrew Wittmann - AnalystBrent Thielman - AnalystOperatorGood afternoon, everyone, and thank you for participating in today's conference call to discuss Concrete Pumping Holdings' financial results for the fourth quarter and full year ended October 31st, 2025. Joining ...

Phoenix Education Partners (NYSE:PXED) Q1 2026 Earnings call January 13, 2026 05:00 PM ET Company ParticipantsJeff Silber - Business and Industrial Services and EducationChris Lynne - CEOBlair Westbloom - CFOBeth Coronelli - VP of Investor RelationsGriffin Boss - Equity ResearchJasper Bibb - VP, Equity ResearchGeorge Tong - Senior Research, Business ServicesAlex Paris - President and Senior Managing DirectorGreg Parrish - VP, Equity ResearchStephanie Moore - SVP, Equity ResearchConference Call ParticipantsR ...

Park Aerospace (NYSE:PKE) Q3 2026 Earnings call January 13, 2026 05:00 PM ET Company ParticipantsBrian Shore - Chairman and CEOMark Esquivel - President and COOOperatorGood morning. My name is Shamali, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Park Aerospace Corp.'s Third Quarter, Fiscal Year 2026 Earnings Release Conference Call and Investor Presentation. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, ...

Concrete Pumping (NasdaqCM:BBCP) Q4 2025 Earnings call January 13, 2026 05:00 PM ET Company ParticipantsIain Humphries - CFOCody Slach - External Director of Investor RelationsBruce Young - CEOConference Call ParticipantsTim Mulrooney - AnalystAndrew Wittmann - AnalystBrent Thielman - AnalystOperatorGood afternoon, everyone, and thank you for participating in today's conference call to discuss Concrete Pumping Holdings' financial results for the fourth quarter and full year ended October 31st, 2025. Joining ...

Powering how Americans save, spend, and invest in health Copyright © 2026 HealthEquity, Inc. All rights reserved. | HealthEquity does not provide legal, tax or financial advice. Investor presentation 1 #1 HSA provider 1 in 4 HSAs in the US are with us +100k clients 200+ Network partners 10.1M HSAs +6% YoY $34.4B HSA assets +15% YoY 17.3M Total Accounts +5% YoY Source: HealthEquity key metrics reported as of Oct 31, 2025. #1 HSA by number of accounts based on 2025 Midyear Devenir HSA report, October 9, 2025. ...

Park Aerospace (NYSE:PKE) Q3 2026 Earnings call January 13, 2026 05:00 PM ET Speaker1Good morning. My name is Shamali, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Park Aerospace Corp.'s Third Quarter, Fiscal Year 2026 Earnings Release Conference Call and Investor Presentation. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question du ...

J.P. Morgan Healthcare Conference Dan Scavilla President and Chief Executive Officer January 13, 2026 Forward-Looking Statements and Associated Risks This presentation contains statements that do not directly and exclusively relate to historical facts which constitute forward-looking statements, including, statements and projections concerning, among other things, the Company's return-to-growth action plan described in this presentation and statements and projections regarding the Company's use of technolog ...

Company Strategy & Pipeline - Zai Lab is executing a dual-engine growth strategy, leveraging a commercially profitable China platform to power global innovation, with the first U S approval expected by 2028[6] - The company aims to expand its global pipeline to over 9 indications in development by 2030[10, 12] - Zai Lab is focused on oncology and immunology, utilizing next-generation biologic modalities like ADCs and BsAbs, targeting validated targets with proven biology[16] Zoci (ZL-1310) Development - Zoci, a DLL3 ADC, is in a pivotal study and shows data supportive of potential best-in-class status[10] - In 2L SCLC, Zoci demonstrated a 68 4% ORR (Objective Response Rate)[32] - Grade ≥3 TRAEs (Treatment-Related Adverse Events) were 13% with Zoci at the selected Phase 3 dose[32] - Zai Lab anticipates a potential first global approval for Zoci in 2028, targeting a $9+ billion total addressable market across SCLC & NEC[40] Financial Position - The company reported a robust cash position of $817 2 million as of September 30, 2025[10, 20] - 48% of revenue was invested in R&D in 9M 2025[70] ZL-1503 (IL13/IL31R) Development - ZL-1503, a dual IL-13 / IL-31R bispecific antibody, is in a global Phase 1/1b study for Mod-to-Sev AD (Atopic Dermatitis)[19, 49] - Preclinical data showed rapid itch suppression sustained for up to 133 days in non-human primates[50]

Phoenix Education Partners (NYSE:PXED) Q1 2026 Earnings call January 13, 2026 05:00 PM ET Speaker4Good afternoon and welcome to Phoenix Education Partners First Quarter Fiscal 2026 Earnings Conference Call. Today's call is being recorded. At this time, all participants are in a listen-only mode. Following prepared remarks, we will open the call for questions. I would now like to turn the call over to Beth Coronelli, Vice President of Investor Relations. Please go ahead.Speaker2Welcome to the Phoenix Educati ...

Siemens Healthineers AG J.P. Morgan Healthcare Conference, January 13, 2026 Unrestricted © Siemens Healthineers, 2026 Unrestricted © Siemens Healthineers, 2025 This webcast has been provided solely for use at this meeting. By attending the meeting or accessing this webcast, you agree to be bound by the following limitations. This webcast is provided in conjunction with an oral presentation and should not be taken out of context. This webcast serves for information purposes only and the information contained ...